SECsense Logo

Amgen Inc. 8-K Report: Key Financial Insights and Debt Financing Update

$AMGN
Form 8-K
Filed on: 2025-05-27
Source
Amgen Inc. 8-K Report: Key Financial Insights and Debt Financing Update

Based on the provided section of the financial report, here are the key extracts and insights:

  1. Entity Information:
  • Company Name: Amgen Inc.
  • CIK (Central Index Key): 0000318154
  • Form Type: 8-K
  • Date of Filing: May 23, 2025
  • Address: One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
  • Phone Number: (805) 447-1000
  1. Stock Information:
  • Common Stock: Par value of $0.0001
  • Stock Ticker Symbol: AMGN (listed on NASDAQ)
  1. Debt Instruments:
  • Senior Notes:
    • Type: 2.00% Senior Notes
    • Maturity: Due in 2026
    • Ticker Symbol: AMGN26 (listed on NASDAQ)
  1. Reporting Period:
  • The report pertains to a specific date: May 23, 2025, indicating that the information may reflect an event or status as of that date.
  1. Segment Information:
  • There are references to segments regarding financial reporting, specifically noting:
    • A classification related to "Senior Notes Due 2026"
    • A classification for "Common Stock"

Insights:

  • The filing is a current report (8-K), which typically indicates a significant event or material change that may affect the company's financial position or operations.
  • The issuance of 2.00% Senior Notes due in 2026 suggests that Amgen is likely raising capital through debt financing, which could either be for new projects, refinancing existing debt, or other corporate purposes.
  • The company continues to maintain its common stock listing on NASDAQ, indicating a stable public presence.
  • The low par value of the common stock suggests that Amgen has a significant number of shares outstanding, typical of large corporations.

Overall, this report indicates Amgen's ongoing financial activities and positions, particularly related to debt financing and stock structure as of the specified date.